Caroline E. Weibull

Caroline E. Weibull

Auto-generated profile, based on publicly available information

Caroline E. Weibull

Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in American Journal of Hematology
Verified
Journal Article
Open access
CRCecilia Radkiewicz
Cecilia Radkiewicz
JBJohanna B. Bruchfeld
Johanna B. Bruchfeld
CWCaroline E. Weibull
Caroline E. Weibull
MJMathias L. Jeppesen
Mathias L. Jeppesen
HHenrik Frederiksen
Henrik Frederiksen
TWTove Wästerlid
Tove Wästerlid
It is well established that the male sex is associated with increased risk for, as well as poorer survival of, most cancers. A similar pattern has been described in lymphomas but has not yet been comprehensively assessed. In this nationwide population‐based cohort study, we used the Swedish Lymphoma Register to investigate sex differences in lymphoma subtype incidence and excess mortality in adults (age 18–99) diagnosed in 2000–2019. Male‐to‐female incidence rate ratios (IRRs) and excess mortality ratios (EMRs) adjusted for age and calendar year were predicted using Poisson regression. We identified 36 795 lymphoma cases, 20 738 (56.4%) in men and 16 057 (43.6%) in women. Men were at significantly higher risk of 14 out of 16 lymphoma subtypes with IRRs ranging from 1.15 (95% confidence interval [CI] 1.09–1.22) in follicular lymphoma to 5.95 (95% CI 4.89–7.24) in hairy cell leukemia. EMRs >1 were seen in 13 out of 16 lymphoma subtypes indicating higher mortality in men, although only statistically significant for classical Hodgkin lymphoma 1.26 (95% CI 1.04–1.54), aggressive lymphoma not otherwise specified 1.29 (95% CI 1.08–1.55), and small lymphocytic lymphoma 1.52 (95% CI 1.11–2.07). A corresponding analysis using data from the Danish Lymphoma Register was performed with comparable results. In conclusion, we demonstrate a significantly higher incidence and trend toward higher mortality in men for most lymphoma subtypes. Future studies with large patient material that include detailed clinicopathological prognostic factors are warranted to further delineate and explain sex differences in lymphoma survival to enable optimal management of lymphoma patients regardless of sex.

31 October 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
KSKarin Sundstrom
Karin Sundstrom
CWCaroline E. Weibull
Caroline E. Weibull
KSKarin Söderberg-Löfdal
Karin Söderberg-Löfdal
ABand Tomas Bergström
and Tomas Bergström
PSPär Sparén
Pär Sparén
LALisen Arnheim-Dahlström
Lisen Arnheim-Dahlström
More detailed understanding of herpes zoster (HZ) is called for in the context of an increasing observed frequency of disease, and ongoing discussions regarding potential consequences of the disease. Thus, population-based data on incidence and complications of HZ are needed. We conducted a register-based cohort study in Västra Götaland County (population 1.5 million) in Sweden. We collected data on all patients diagnosed with HZ during the years 2008 to 2010 from population-based registers. Incidence rates (IR) of HZ and related complications were calculated and stratified by age and sex. There were 13 269 new HZ cases during the study period. Overall, the IR of herpes zoster in both genders was 3.25 (95 % CI: 3.16–3.34) per 1000 person years in 2010. The incidence was consistently higher in women than in men and in older than in young. A history of immunosuppression was more common than in the general population. The incidence was highest in individuals over 80 years of age (IR 9.2 per 1000 person years, 95 % CI: 8.8–9.6) during 2008–2010. The most common complications to HZ were ocular engagement and postherpetic neuralgia; risks for stroke and sepsis were significantly elevated during the one year following diagnosis, especially in the youngest age group of patients 0–39 years. Herpes zoster is more common in women, the elderly and immunosuppressed individuals. We verify a population-based association between herpes zoster and risk for stroke and sepsis, which may merit concern.

8 March 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JRJoana M. Rodrigues
Joana M. Rodrigues
ANAnna Nikkarinen
Anna Nikkarinen
PHPeter Hollander
Peter Hollander
CWCaroline E. Weibull
Caroline E. Weibull
RRRiikka Räty
Riikka Räty
IGIngrid Glimelius
Ingrid Glimelius
Summary: We characterised patients with mantle cell lymphoma (MCL) with poor prognosis based on differences in immune infiltration. Different expressions of the tumour cell markers Cyclin D1 and sex‐determining region Y‐box transcription factor 11 (SOX11), and the immune markers cluster of differentiation 3 (CD3), CD4, CD8, CD25, forkhead box protein P3 (FoxP3), T‐box transcription factor TBX21 (T‐bet), programmed cell death protein 1 (PD‐1), programmed‐death ligand 1 (PD‐L1) and CD163 were investigated for all‐cause mortality in 282 patients with MCL and time‐to‐progression (TTP) in 106 clinical trial patients. With increasing age, a significantly lower infiltration of CD3+ T lymphocytes was seen. T‐cell infiltration was independent of cellular tumour antigen p53 (p53) expression, Ki‐67, morphology and frequency of tumour cells. The all‐cause mortality was higher in patients with PD‐L1‐expression above cut‐off [hazard ratio (HR) 1·97, 95% confidence interval (CI) 1·18–3·25, adjusted for sex and MCL International Prognostic Index (MIPI)] and a higher frequency of CD163+ cells (continuously, HR 1·51, 95% CI 1·03–2·23, adjusting for age, sex, morphology, Ki‐67 and p53). In patients treated within the Nordic Lymphoma Group MCL2/3 trials, TTP was shorter in patients with a higher frequency of FoxP3+ cells (HR 3·22, 95% CI 1·40–7·43) and CD163+ cells (HR 6·09, 95% CI 1·84–20·21), independent of sex and MIPI. When combined a higher frequency of CD163+ macrophages and PD‐L1+ cells or high CD163+ macrophages and FoxP3+ regulatory T cells indicated worse outcome independent of established risk factors. The T‐cell infiltrate was in turn independent of molecular characteristics of the malignant cells and decreased with age.

1 February 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CWCaroline E. Weibull
Caroline E. Weibull
SESandra Eloranta
Sandra Eloranta
KSKarin E. Smedby
Karin E. Smedby
MBMagnus Björkholm
Magnus Björkholm
SKSigurdur Y. Kristinsson
Sigurdur Y. Kristinsson
IGIngrid Glimelius
Ingrid Glimelius
Purpose: Many patients and clinicians are worried that pregnancy after the diagnosis of Hodgkin lymphoma (HL) may increase the risk of relapse despite a lack of empirical evidence to support such concerns. We investigated if an association exists between pregnancy and relapse in women with a diagnosis of HL. Materials and Methods: Using Swedish healthcare registers combined with medical records, we included 449 women who received a diagnosis of HL between 1992 and 2009 and who were age 18 to 40 years at diagnosis. Follow-up started 6 months after diagnosis, when the patients' condition was assumed to be in remission. Pregnancy-associated relapse was defined as a relapse during pregnancy or within 5 years after delivery. Hazard ratios (HRs) with 95% CIs were estimated by using the Cox proportional hazards model. Results: Among the 449 women, 144 (32%) became pregnant during follow-up. Overall, 47 relapses were recorded, of which one was a pregnancy-associated relapse. The adjusted HR for the comparison of the pregnancy-associated relapse rate to the non–pregnancy-associated relapse rate was 0.29 (95% CI, 0.04 to 2.18). The expected number of relapses in women with a recent pregnancy, given that they would experience the same relapse rate as that of women without a recent pregnancy, was 3.76; the observed-to-expected ratio was 0.27 (95% exact CI, 0.01 to 1.51). Conclusion: We found no evidence that a pregnancy after diagnosis increases the relapse rate among women whose HL is in remission. Survivors of HL need to consider a range of factors when deciding about future reproduction. However, given the results of this study, the risk of pregnancy-associated relapse does not need to be considered.

23 May 2018 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MBMagnus Björkholm
Magnus Björkholm
CWCaroline E. Weibull
Caroline E. Weibull
SESandra Eloranta
Sandra Eloranta
KSKarin E. Smedby
Karin E. Smedby
IGIngrid Glimelius
Ingrid Glimelius
PDPaul W. Dickman
Paul W. Dickman

17 March 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
DBDaniel Moreno Berggren
Daniel Moreno Berggren
HGHege Garelius
Hege Garelius
PHPetter Willner Hjelm
Petter Willner Hjelm
LNLars Nilsson
Lars Nilsson
BRBengt Rasmussen
Bengt Rasmussen
EEElisabeth Ejerblad
Elisabeth Ejerblad
In this population-based study, we aimed to characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS) and define the implications of type of previous treatment and primary disease. We combined data from MDS patients, diagnosed between 2009 and 2017 (n = 2705), in the nationwide Swedish MDS register, with several health registers. Furthermore, using matched population controls, we investigated the prevalence of antecedent malignancies in MDS patients in comparison with the general population. This first ever nationwide study on t-MDS confirms a shorter median survival for t-MDS compared to de novo MDS (15.8 months vs 31.1 months, p < 0.001). T-MDS patients previously treated with radiation only had disease characteristics with a striking resemblance to de novo-MDS, in sharp contrast to patients treated with chemotherapy who had a significantly higher risk profile. IPSS-R and the WHO classification differentiated t-MDS into different risk groups. As compared with controls, MDS patients had a six-fold increased prevalence of a previous hematological malignancy but only a 34% increased prevalence of a previous solid tumor. T-MDS patients with a previous hematological malignancy had a dismal prognosis, due both to mortality related to their primary disease and to high-risk MDS.